This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Th2 cells | |
|---|---|
| Name | Th2 cells |
| Lineage | CD4+ T lymphocytes |
| Markers | GATA3, CCR4, CCR8 |
| Primary cytokines | IL-4, IL-5, IL-13 |
| Functions | B cell help, eosinophil activation, allergic inflammation |
Th2 cells are a subset of CD4+ helper T lymphocytes characterized by production of interleukins that promote humoral immunity and allergic inflammation. They are defined by expression of the transcription factor GATA3 and chemokine receptors that direct tissue homing. Th2 responses are central to defense against helminths and influence vaccine responses, allergy, and asthma.
Th2 cells arise from naive CD4+ T cells following antigen recognition mediated by the T cell receptor and costimulatory signals from antigen-presenting cells such as dendritic cells, macrophages, and B cells in lymphoid organs like the spleen and lymph nodes. Key molecular signals include cytokines and transcription factors that bias differentiation toward a Th2 phenotype; these signals are influenced by pathogens including helminths, environmental allergens, and components of microbiota. Th2-mediated immunity interfaces with other immune components including B cells in germinal centers, eosinophils in inflamed tissues, basophils in peripheral blood, and innate lymphoid cells in barrier sites.
Naive CD4+ T cells receive T cell receptor stimulation in the context of MHC class II presented by dendritic cells and costimulation via CD28 and ICOS; this activation occurs in lymph nodes and mucosal-associated lymphoid tissues such as Peyer’s patches. Polarizing cytokines such as IL-4 initiate a positive feedback loop activating STAT6 and inducing GATA3, which stabilizes the Th2 program and upregulates receptors like CCR4 and CCR8 for trafficking to skin and lung. Transcriptional cooperation involves NFAT, AP-1, and chromatin remodeling complexes; epigenetic modifications at the IL4/IL5/IL13 locus are influenced by signals from basophils, mast cells, and follicular helper T cells in germinal centers. Antigen strength, co-stimulatory molecules including OX40/OX40L and Notch ligands, and environmental cues from the microbiota, helminth antigens, and epithelial-derived alarmins such as IL-25 and IL-33 shape lineage commitment.
Th2 cells characteristically secrete IL-4, IL-5, IL-13, and to a lesser extent IL-9 and IL-10; these cytokines drive class switching in B cells toward IgE and IgG4, activate eosinophils, and promote mucus production and smooth muscle hyperreactivity in airway tissues. IL-4 signals through the IL-4 receptor alpha chain and STAT6 to enforce the Th2 program and induce class-switch recombination in B cells within germinal centers of lymphoid follicles. IL-5 is crucial for eosinophilopoiesis in the bone marrow and survival of eosinophils recruited to allergic lesions; IL-13 acts on epithelial cells and fibroblasts to mediate tissue remodeling and goblet cell metaplasia. Th2 effector functions are executed at barrier sites such as the lung, skin, and gut and involve cross-talk with mast cells, basophils, and type 2 innate lymphoid cells.
Th2 responses are protective against extracellular parasites, notably helminths and certain protozoa, by orchestrating granuloma formation and promoting expulsion mechanisms mediated by mucus and smooth muscle contraction. Dysregulated or exaggerated Th2 activity underlies atopic diseases including atopic dermatitis, allergic rhinitis, and eosinophilic asthma, and contributes to conditions such as chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis. Th2-driven IgE responses facilitate immediate-type hypersensitivity via mast cell degranulation, linking to clinical manifestations cataloged in epidemiologic studies and clinical trials conducted by academic centers and regulatory agencies. Conversely, impaired Th2 responses can affect vaccine efficacy against pathogens that require strong humoral immunity and can influence outcomes in coinfections including HIV and tuberculosis.
Th2 differentiation and function are antagonized by Th1 and Th17 pathways through cytokines such as IFN-γ and IL-17 and transcription factors including T-bet and RORγt; reciprocal inhibition involves STAT and SOCS family members. Regulatory T cells and tolerogenic dendritic cells restrain Th2-mediated pathology via IL-10 and TGF-β, and immune checkpoints such as PD-1 modulate effector activity. Cross-talk with follicular helper T cells within germinal centers determines isotype selection and affinity maturation by interacting with B cell surface molecules including CD40L; competition for antigen and cytokine milieu shapes the balance among helper subsets during infection, vaccination, autoimmunity, and allergy.
Therapeutic strategies targeting Th2 pathways have transformed management of allergic and eosinophilic diseases: monoclonal antibodies against IL-4Rα, IL-5, IL-13, and IgE have been developed and evaluated in randomized controlled trials sponsored by academic institutions and pharmaceutical companies and approved by regulatory agencies. Small molecules and biologics modulating upstream alarmins such as TSLP, IL-33, or OX40/OX40L are in clinical development, and interventions altering dendritic cell activation or microbiome composition aim to prevent maladaptive Th2 polarization. Biomarkers including blood eosinophil counts, serum IgE, and fractional exhaled nitric oxide inform stratified therapy in precision medicine programs at tertiary centers. Ongoing research in animal models, cohort studies, and translational trials continues to refine approaches to augment protective Th2 responses against parasites while limiting pathological allergic inflammation.
Category:Immune cells